Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is focused on developing novel biotechnology treatments that target the Wnt pathway, with a promising pipeline of drug candidates for retinal diseases such as wet AMD and DME. The company's recent updates and preclinical data demonstrate the potential of their lead compound, SZN-8141, to effectively address the unmet need for durable and impactful treatments in retinal vascular diseases. With a strong cash balance and a partnership with Boehringer Ingelheim, Surrozen is poised for success in bringing its Wnt agonist therapies to market and establishing itself as a leader in the field.

Bears say

Surrozen is a clinical-stage biotechnology company working on drug candidates that target the Wnt pathway for tissue repair. While they have several product candidates in development, including SZN-8141 and SZN-413, the company's financials show a net loss of $242 million in 2025 and limited cash on hand. However, our negative outlook is primarily due to the potential risks associated with the success and adoption of these new treatments, as well as the possibility of unexpected toxicity or competition from other therapies. We believe that these factors could hinder the company's ability to generate significant revenue and ultimately impact the perceived value of their drugs in the market.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.